NCT01435421

Brief Summary

Acute liver failure (ALF) results from an abrupt loss of hepatic metabolic and synthetic function and leads to encephalopathy and potentially multi-organ dysfunction. Aetiologies include autoimmune and metabolic diseases, infectious agents and hepatotoxins. Worldwide, infectious hepatitis (A, B and E) is the most common cause. In Western Europe and the USA, ALF is most frequently caused by paracetamol intoxication. The MBT can produce immediate results to aid in decision making in patients with acute liver disease. Such a test may affect decision-making regarding transplantation in this setting, facilitate appropriate discharge from critical care to other hospital units and to home, provide point of care assessment of therapeutic interventions. The BreathID can potentially help in determining:

  • Parameter to include patients in transplant list (the UNOS 1A group)
  • Identification that patient deteriorates and needs extended hospitalization/referral to ICU/change in management
  • An addition to the MELD and or other scores to estimate risk in other acute patients
  • Additional information to that of other commonly utilized prognostic scoring systems The primary end-point of the study is to develop a model to predict deterioration of the liver disease, which incorporates measurements from the MBT along with other potential variables. The data collected will be used to develop a prediction model using data-mining methodology (linear and non-linear regression models, binary trees, neural networks, etc…). The predictive models may include measurements from the MBT, blood test results, as single measurements or as trend over time. The model that will be developed, will attempt to predict the disease deterioration vs. recovery accurately, at an earlier time point than the standard procedure. A threshold will then be determinate based on adequate sensitivity and specificity levels.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
112

participants targeted

Target at P50-P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 15, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 16, 2011

Completed
15 days until next milestone

Study Start

First participant enrolled

October 1, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Last Updated

September 16, 2011

Status Verified

September 1, 2011

Enrollment Period

1.2 years

First QC Date

September 15, 2011

Last Update Submit

September 15, 2011

Conditions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients that are hospitalaized.

You may qualify if:

  • Adult men or women (\>18 years of age).
  • Acute Liver insult
  • No evidence of cirrhosis (unless clinical acute Wilsons)
  • INR \> 1.5
  • Duration of illness \< 24 weeks -

You may not qualify if:

  • Patient with any chronic liver disease
  • Patient has severe congestive heart failure
  • Patient has severe pulmonary hypertension
  • Patient has chronic renal insufficiency with severe cardiac disease
  • Patient has previous surgical bypass surgery for morbid obesity
  • Patient has extensive small bowel resection
  • Patient with established extra-hepatic auto-immune disease on long term treatment
  • Patient is a recipient of any organ transplant (within the last 3 months)- Patient with proven or suspected hepatocellular carcinoma
  • Patient is pregnant
  • Patient allergic to paracetamol (such as Tylenol or any other related medications)
  • Patients in whom oral intake is contra-indicated
  • Patient, based on the opinion of the investigator, should not be enrolled into this study
  • Patients or their nominated representative is unwilling to sign informed consent
  • Patients that are participating in other clinical trials evaluating experimental treatments or procedures, not including observatory trials -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Liver Failure, Acute

Condition Hierarchy (Ancestors)

Liver FailureHepatic InsufficiencyLiver DiseasesDigestive System Diseases

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 15, 2011

First Posted

September 16, 2011

Study Start

October 1, 2011

Primary Completion

December 1, 2012

Last Updated

September 16, 2011

Record last verified: 2011-09